Allergan dermatology, ophthalmic news

Allergan said it will reduce headcount by about 1,500 (13%) to about 10,200. The cuts include about 700 R&D positions and about 250 positions from the company’s sales force. Allergan said all R&D programs that are in the clinic will continue, but the company cut a number of earlier stage programs, including a preclinical acne program and Phase I programs in rosacea and glaucoma. The company will have about 1,450 R&D positions and 1,450 sales positions after the cuts. Allergan said it will also eliminate an additional 250 vacant positions. The company said the cuts will generate pre-tax savings of about $475 million in 2015. As of June 30, the company had $3.7 billion in cash and a six-month non-GAAP operating gain of $1.2 billion. ...